SCHEMBL5093776

SCHEMBL5093776

CSc1nccc(-n2[nH]c(=O)c3ccccc32)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.43
MAPK1 P28482 1/20 0.43
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
LDHA P00338 1/20 0.40
HPGD P15428 5/20 0.39
CYP1A2 P05177 3/20 0.39
CYP2C19 P33261 3/20 0.39
MAPT P10636 3/20 0.39
CYP3A4 P08684 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP2C9 P11712 1/20 0.37
TSHR P16473 1/20 0.36
TGFBR1 P36897 2/20 0.35
ELANE P08246 1/20 0.35
PARP1 P09874 1/20 0.34
TGFBR2 P37173 1/20 0.34
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19337052 0.81 RPS6KA5 (0.46) GAAMAPK1MEN1KMT2ALDHA
SCHEMBL5096134 0.71 ALDH1A1 (0.39) GAAMEN1KMT2AMAPTALDH1A1
SCHEMBL30305668 0.71 GAA (0.55) GAAMAPK1MEN1KMT2ALDHA
SCHEMBL3821081 0.70 ALDH1A1 (0.39) GAAMEN1KMT2AHPGDMAPT
SCHEMBL5102168 0.70 CDK2 (0.63) GAAMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL3807376 0.69 MAPK8 (0.62) CYP2C9
SCHEMBL3807372 0.69 MAPK8 (0.62) CYP2C9
SCHEMBL1813376 0.69 LDHA (0.54) MEN1KMT2ALDHAHPGDCYP1A2
SCHEMBL3817520 0.68 CYP11B1 (0.40) GAAMEN1KMT2AHPGDCYP1A2
SCHEMBL7024738 0.68 ROCK1 (0.62) RPS6KA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399462-B2 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain ROCHE PALO ALTO LLC (US) 2013-03-19 US disclosed
US-8399462-B2 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain ROCHE PALO ALTO LLC (US) 2013-03-19 US disclosed
US-8399462-B2 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain ROCHE PALO ALTO LLC (US) 2013-03-19 US disclosed
WO-2008068171-A9 SUBSTITUTED PYRIMIDINES AND THEIR USE AS JNK MODULATORS HOFFMANN LA ROCHE (CH) 2009-07-16 WO disclosed
US-20080146565-A1 JNK modulators ROCHE PALO ALTO LLC 2008-06-19 US disclosed
US-20080146565-A1 JNK modulators ROCHE PALO ALTO LLC 2008-06-19 US disclosed
WO-2008068171-A1 SUBSTITUTED PYRIMIDINES AND THEIR USE AS JNK MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146565-A1 JNK modulators MAPKAPK2, MAPKAPK3, MAP3K10 GAA 4330/4885MAPK1 17/4885MEN1 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.